EP Patent

EP3650013A1 — Combination formulation of two antiviral compounds

Assigned to Gilead Pharmasset LLC · Expires 2020-05-13 · 6y expired

What this patent protects

Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.

USPTO Abstract

Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.

Drugs covered by this patent

Patent Metadata

Patent number: EP3650013A1
Jurisdiction: EP
Classification: —
Expires: 2020-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.